Related Experiment Video

Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins in Heart Failure

Michele Correale1, Silvia Abruzzese, Carmen Adriana Greco

  • 1Department of Cardiology, University of Foggia, Viale Pinto 1, 71100 Foggia, Italy. nd.brunetti@unifg.it.

Current Vascular Pharmacology
|September 29, 2012
PubMed

Insights

Statins significantly reduce cardiovascular events and mortality. This review explores their role in preventing heart failure (HF) for patients with coronary artery disease, summarizing key evidence.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins are proven to reduce cardiovascular morbidity and mortality in primary and secondary prevention.
  • Evidence suggests statins can prevent acute coronary syndromes.
  • Statins may also play a role in preventing heart failure (HF).

Purpose of the Study:

  • To review the experimental and clinical evidence on statin therapy in heart failure management.
  • To consolidate current understanding of statins' impact on HF.
  • To assess the efficacy of statins in HF prevention and treatment.

Main Methods:

  • Literature review of experimental studies.
  • Analysis of clinical trial data.
  • Synthesis of evidence on statins and heart failure.

Main Results:

  • Statins demonstrate a significant reduction in cardiovascular events.
  • Studies indicate statins' efficacy in preventing acute coronary syndromes.
  • Evidence supports statins' potential in preventing heart failure in specific patient groups.

Conclusions:

  • Statins are crucial for cardiovascular event reduction.
  • Statins show promise in preventing heart failure in patients with coronary artery disease.
  • Further research confirms the multifaceted role of statins in cardiovascular health management.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...